甲状腺激素类药物治疗在非酒精性脂肪性肝炎中的研究进展

Progress in The Treatment of Thyroid Hormones in Non-alcoholic Steatohepatitis

非酒精性脂肪性肝炎(NASH)现已成为临床常见的肝脏代谢类疾病,且目前市面上无治疗该病的确切药物,因此,探寻治疗该病的相关药物已成为医学界和社会各界人士重点关注的问题。经临床多次研究结果提示,肝脏特异性水平表达的甲状腺受体β在发生纸质代谢过程中起到了巨大作用。医学上根据甲状腺激素受体β研发的人工合成的三碘甲状腺原氨酸(T3)与甲状腺激素受体(TR)β特异性激动剂,在多项研究的结果中表明能够增加肝脏内胆固醇的清理,抑制其肝脏甘油三脂(TG)的合成,减少肝脏内脂质的沉淀,促进肝脏糖代谢及降低其炎症,已成为临床治疗NASH疾病的常用治疗药物。本文通过甲状腺激素受体β为靶点,对NASH疾病的发病机制以及临床治疗研究进行综述,有望对临床治疗NASH疾病提供帮助。

Non-alcoholic steatohepatitis(NASH)has become a common clinical liver metabolic disease,and there are no exact drugs for the treatment on the market.Therefore,exploring the treatment of related drugs for the disease has become a focus of concern in the medical community and people from all walks of life.The results of several clinical studies suggest that thyroid receptors expressed at liver-specific levels play a huge role in the development of paper-based metabolism.Medical according to the thyroid hormone receptor research and development of synthetic triiodothyronine(T3)and thyroid hormone receptor(TR)specific agonist,in a number of studies can increase the cleaning of cholesterol in the liver,inhibit the liver triglycerides(TG)synthesis,reduce lipid precipitation in the liver,promote liver glucose metabolism and reduce its inflammation,has become a common treatment for clinical treatment of NA SH disease drugs.This paper reviews the pathogenesis of NA SH disease and the clinical treatment research,which is expected to provide help in the clinical treatment of NA SH disease.